Role of omega-3 PUFA-derived mediators, the protectins, in influenza virus infection

Clark, 2011, Influenza: epidemiology, clinical features, therapy, and prevention, Semin. Respir. Crit. Care Med., 32, 373, 10.1055/s-0031-1283278 Beigel, 2005, Avian influenza A (H5N1) infection in humans, N. Engl. J. Med., 353, 1374, 10.1056/NEJMra052211 Imai, 2012, The role of receptor binding specificity in interspecies transmission of influenza viruses, Curr. Opin. Virol., 2, 160, 10.1016/j.coviro.2012.03.003 WHO Shankaran, 2012, Influenza virus resistance to neuraminidase inhibitors: implications for treatment, Curr. Infect. Dis., 14, 155, 10.1007/s11908-012-0236-x Kumar, 2011, Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life, J. Antimicrob. Chemother., 66, 959, 10.1093/jac/dkr090 Kumar, 2010, Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection, Pediatr. Infect. Dis. J., 29, 591, 10.1097/INF.0b013e3181d73e32 Karlas, 2010, Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication, Nature, 463, 818, 10.1038/nature08760 Hao, 2008, Drosophila RNAi screen identifies host genes important for influenza virus replication, Nature, 454, 890, 10.1038/nature07151 Konig, 2010, Human host factors required for influenza virus replication, Nature, 463, 813, 10.1038/nature08699 Shapira, 2009, A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection, Cell, 139, 1255, 10.1016/j.cell.2009.12.018 Josset, 2013, Moving H5N1 studies into the era of systems biology, Virus Res., 178, 151, 10.1016/j.virusres.2013.02.011 Ritter, 2010, Metabolic effects of influenza virus infection in cultured animal cells: intra- and extracellular metabolite profiling, BMC Syst. Biol., 4, 61, 10.1186/1752-0509-4-61 Lin, 2010, GC/MS-based metabolomics reveals fatty acid biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus, Talanta, 83, 262, 10.1016/j.talanta.2010.09.019 Russell, 2014, The role of pro-resolution lipid mediators in infectious disease, Immunology, 141, 166, 10.1111/imm.12206 Cilloniz, 2010, Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection, J. Virol., 84, 7613, 10.1128/JVI.00553-10 Shirey, 2014, Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology, Mucosal Immunol., 7, 549, 10.1038/mi.2013.71 Genis, 1992, Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage–astroglia interactions: implications for the neuropathogenesis of HIV disease, J. Exp. Med., 176, 1703, 10.1084/jem.176.6.1703 Morita, 2013, The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza, Cell, 153, 112, 10.1016/j.cell.2013.02.027 Rajasagi, 2013, Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology, Invest. Ophthalmol. Vis. Sci., 54, 6269, 10.1167/iovs.13-12152 Rajasagi, 2011, Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1, J. Immunol., 186, 1735, 10.4049/jimmunol.1003456 Neumann, 2004, Orthomyxovirus replication, transcription, and polyadenylation, Curr. Top. Microbiol. Immunol., 283, 121 De Clercq, 2006, Antiviral agents active against influenza A viruses, Nat. Rev. Drug Discov., 5, 1015, 10.1038/nrd2175 Abdel-Ghafar, 2008, Update on avian influenza A (H5N1) virus infection in humans, N. Engl. J. Med., 358, 261, 10.1056/NEJMra0707279 Schwab, 2007, Resolvin E1 and protectin D1 activate inflammation–resolution programmes, Nature, 447, 869, 10.1038/nature05877 Serhan, 2007, Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways, Annu. Rev. Immunol., 25, 101, 10.1146/annurev.immunol.25.022106.141647 Serhan, 2011, Resolvins and protectins in inflammation resolution, Chem. Rev., 111, 5922, 10.1021/cr100396c Isobe, 2012, Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation, Front. Immunol., 3, 270, 10.3389/fimmu.2012.00270 Chiang, 2005, Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX, Prostaglandins Leukot. Essent. Fat. Acids, 73, 163, 10.1016/j.plefa.2005.05.003 Serhan, 2006, Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes, J. Immunol., 176, 1848, 10.4049/jimmunol.176.3.1848 Serhan, 2014, Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome, Biochim. Biophys. Acta., S1388-1981 Serhan, 2002, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals, J. Exp. Med., 196, 1025, 10.1084/jem.20020760 Duffield, 2006, Resolvin D series and protectin D1 mitigate acute kidney injury, J. Immunol., 177, 5902, 10.4049/jimmunol.177.9.5902 Arita, 2012, Mediator lipidomics in acute inflammation and resolution, J. Biochem., 152, 313, 10.1093/jb/mvs092 Yamada, 2011, Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice, FASEB J., 25, 561, 10.1096/fj.10-170027 Levy, 2007, Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness, J. Immunol., 178, 496, 10.4049/jimmunol.178.1.496 Sun, 1996, Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein, J. Biol. Chem., 271, 24055, 10.1074/jbc.271.39.24055 Chanez, 2002, 15-lipoxygenase: a Janus enzyme?, Am. J. Respir. Cell Mol. Biol., 27, 655, 10.1165/rcmb.F253 Gruter, 1998, TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus, Mol. Cell, 1, 649, 10.1016/S1097-2765(00)80065-9 Herold, 2000, TAP (NXF1) belongs to a multigene family of putative RNA export factors with a conserved modular architecture, Mol. Cell. Biol., 20, 8996, 10.1128/MCB.20.23.8996-9008.2000 Katahira, 1999, The Mex67p-mediated nuclear mRNA export pathway is conserved from yeast to human, EMBO J., 18, 2593, 10.1093/emboj/18.9.2593 Rodriguez-Navarro, 2011, Linking gene regulation to mRNA production and export, Curr. Opin. Cell Biol., 23, 302, 10.1016/j.ceb.2010.12.002 Ho, 2002, The crystal structure and mutational analysis of a novel RNA-binding domain found in the human Tap nuclear mRNA export factor, Proc. Natl. Acad. Sci. U. S. A., 99, 1888, 10.1073/pnas.042698599 Liker, 2000, The structure of the mRNA export factor TAP reveals a cis arrangement of a non-canonical RNP domain and an LRR domain, EMBO J., 19, 5587, 10.1093/emboj/19.21.5587 Reed, 2002, A conserved mRNA export machinery coupled to pre-mRNA splicing, Cell, 108, 523, 10.1016/S0092-8674(02)00627-X Stewart, 2010, Nuclear export of mRNA, Trends Biochem. Sci., 35, 609, 10.1016/j.tibs.2010.07.001 Braun, 1999, TAP binds to the constitutive transport element (CTE) through a novel RNA-binding motif that is sufficient to promote CTE-dependent RNA export from the nucleus, EMBO J., 18, 1953, 10.1093/emboj/18.7.1953 Yatherajam, 2011, Export of adenoviral late mRNA from the nucleus requires the Nxf1/Tap export receptor, J. Virol., 85, 1429, 10.1128/JVI.02108-10 Arya, 2010, The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir, Clin. Pharmacol. Ther., 88, 587, 10.1038/clpt.2010.187 Serhan, 2014, Pro-resolving lipid mediators are leads for resolution physiology, Nature, 510, 92, 10.1038/nature13479 Lukiw, 2005, A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease, J. Clin. Invest., 115, 2774, 10.1172/JCI25420 Levy, 2007, Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism, FASEB J., 21, 3877, 10.1096/fj.07-8653com